A novel composite immunotoxin that suppresses rabies virus production by the infected cells

Journal of Immunological Methods

Volumn 353, Issue 1-2, 2010, Pages 78-86

  Mareeva, Tatiana ^a   Wanjalla, Celestine ^a   Schnell, Matthias J ^a,b,c   Sykulev, Yuri ^a,b,c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Composite immunotoxin; Peptide MHC ligands; Pseudomonas exotoxin; Rabies virus; TCR like antibody

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOTOXIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE VACCINE; PSEUDOMONAS EXOTOXIN; SERYLISOLEUCYLISOLEUCYLASPARAGYLPHENYLALANYLGLUTAMYLLYSYLLEUCINE; STREPTAVIDIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY SPECIFICITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG TARGETING; IMMUNE RESPONSE; IMMUNOTHERAPY; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; RABIES VIRUS; SENSITIZATION; TOXIN ANALYSIS; VACCINE PRODUCTION; VIRUS INHIBITION; VIRUS PARTICLE;

ADP RIBOSE TRANSFERASES; ANIMALS; ANTIBODY SPECIFICITY; ANTIGEN PRESENTATION; ANTIVIRAL AGENTS; BACTERIAL TOXINS; BINDING SITES, ANTIBODY; CELL LINE; CRICETINAE; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DROSOPHILA; EPITOPES; EXOTOXINS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOTOXINS; MICE; OVALBUMIN; PEPTIDE FRAGMENTS; RABIES VIRUS; RECOMBINANT PROTEINS; TIME FACTORS; VIRION; VIRULENCE FACTORS; VIRUS REPLICATION;

PSEUDOMONAS EXOTOXIN; RABIES VIRUS;

EID: 77649270721     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2009.11.010     Document Type: Article

References (40)

1. Amanna I.J., Slifka M.K., Crotty S. Immunity and immunological memory following smallpox vaccination. Immunol. Rev. 2006, 211:320.
2. Anikeeva N., Lebedeva T., Krogsgaard M., Tetin S.Y., Martinez-Hackert E., Kalams S.A., Davis M.M., Sykulev Y. Distinct molecular mechanisms account for the specificity of two different T-cell receptors. Biochemistry 2003, 42:4709.
3. Anikeeva N., Lebedeva T., Sumaroka M., Kalams S.A., Sykulev Y. Soluble HIV-specific T-cell receptor: expression, purification and analysis of the specificity. J. Immunol. Meth. 2003, 277:75.
4. Anikeeva N., Lebedeva T., Clapp A.R., Goldman E.R., Dustin M.L., Mattoussi H., Sykulev Y. Quantum dot/peptide-MHC biosensors reveal strong CD8-dependent cooperation between self and viral antigens that augment the T cell response. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:16846.
5. Anikeeva N., Mareeva T., Liu W., Sykulev Y. Can oligomeric T-cell receptor be used as a tool to detect viral peptide epitopes on infected cells?. Clin. Immunol. 2009, 130:98. (Electronic publication ahead of print, 2008 Oct 8).
6. Bera T.K., Kennedy P.E., Berger E.A., Barbas C.F., Pastan I. Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein. Mol. Med. 1998, 4:384.
7. Biddison W.E., Turner R.V., Gagnon S.J., Lev A., Cohen C.J., Reiter Y. Tax and M1 peptide/HLA-A2-specific Fabs and T cell receptors recognize nonidentical structural features on peptide/HLA-A2 complexes. J. Immunol. 2003, 171:3064.
8. Brinkmann U., Pai L.H., FitzGerald D.J., Willingham M., Pastan I. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:8616.
9. Brown M., Zhang Y., Dermine S., de Wynter E.A., Hart C., Kitchener H., Stern P.L., Skinner M.A., Stacey S.N. Dendritic cells infected with recombinant fowlpox virus vectors are potent and long-acting stimulators of transgene-specific class I restricted T lymphocyte activity. Gene Ther. 2000, 7:1680.
10. Chlewicki L.K., Holler P.D., Monti B.C., Clutter M.R., Kranz D.M. High-affinity, peptide-specific T cell receptors can be generated by mutations in CDR1, CDR2 or CDR3. J. Mol. Biol. 2005, 346:223.
11. Cohen C.J., Denkberg G., Lev A., Epel M., Reiter Y. Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions. J. Mol. Recognit. 2003, 16:324.
12. Drexler I., Staib C., Kastenmuller W., Stevanovic S., Schmidt B., Lemonnier F.A., Rammensee H.G., Busch D.H., Bernhard H., Erfle V., Sutter G. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:217.
13. Feldmann H., Jones S., Klenk H.D., Schnittler H.J. Ebola virus: from discovery to vaccine. Nat. Rev. Immunol. 2003, 3:677.
14. FitzGerald D.J. Recombinant immunotoxins. Antibody Fusion Proteins 1999, 111. Wiley-Liss, Inc. A.A.S.M. Chamow (Ed.).
15. Holler P.D., Holman P.O., Shusta E.V., O'Herrin S., Wittrup K.D., Kranz D.M. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:5387.
16. Kennedy P.E., Bera T.K., Wang Q.C., Gallo M., Wagner W., Lewis M.G., Berger E.A., Pastan I. Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques. J. Leukoc. Biol. 2006, 80:1175.
17. Kreitman R.J., Pastan I. Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem. J. 1995, 307(Pt 1):29.
18. Kreitman R.J., Chaudhary V.K., Waldmann T., Willingham M.C., FitzGerald D.J., Pastan I. The recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:8291.
19. Mareeva T., Lebedeva T., Anikeeva N., Manser T., Sykulev Y. Antibody specific for the peptide-MHC complex: is it TCR-like?. J. Biol. Chem. 2004, 279:44243.
20. Mareeva T., Martinez-Hackert E., Sykulev Y. How a T cell receptor-like antibody recognizes major histocompatibility complex-bound peptide. J. Biol. Chem. 2008, 283:29053.
21. McAllister A., Arbetman A.E., Mandl S., Pena-Rossi C., Andino R. Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases. J. Virol. 2000, 74:9197.
22. Onda M., Beers R., Xiang L., Nagata S., Wang Q.C., Pastan I. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:11311.
23. Pastan I., Chaudhary V., FitzGerald D.J. Recombinant toxins as novel therapeutic agents. Annu. Rev. Biochem. 1992, 61:331.
24. Pastan I., Hassan R., Fitzgerald D.J., Kreitman R.J. Immunotoxin therapy of cancer. Nat. Rev. Cancer 2006, 6:559.
25. Plesa G., McKenna P.M., Schnell M.J., Eisenlohr L.C. Immunogenicity of cytopathic and noncytopathic viral vectors. J. Virol. 2006, 80:6259.
26. Porgador A., Yewdell J.W., Deng Y., Bennink J.R., Germain R.N. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 1997, 6:715.
27. Puri R.K., Ogata M., Leland P., Feldman G.M., FitzGerald D., Pastan I. Expression of high-affinity interleukin 4 receptors on murine sarcoma cells and receptor-mediated cytotoxicity of tumor cells to chimeric protein between interleukin 4 and Pseudomonas exotoxin. Cancer Res. 1991, 51:3011.
28. Reiter Y., Di Carlo A., Fugger L., Engberg J., Pastan I. Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:4631.
29. Root M.J., Hamer D.H. Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:5016.
30. Sherritt M., Cooper L., Moss D.J., Kienzle N., Altman J., Khanna R. Immunization with tumor-associated epitopes fused to an endoplasmic reticulum translocation signal sequence affords protection against tumors with down-regulated expression of MHC and peptide transporters. Int. Immunol. 2001, 13:265.
31. Sullivan N.J., Sanchez A., Rollin P.E., Yang Z.Y., Nabel G.J. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000, 408:605.
32. Sundar K., Boesen A., Coico R. Computational prediction and identification of HLA-A2.1-specific Ebola virus CTL epitopes. Virology 2007, 360:257.
33. Sweeney E.B., Murphy J.R. Diphtheria toxin-based receptor-specific chimaeric toxins as targeted therapies. Essays Biochem. 1995, 30:119.
34. Sweeney E.B., Foss F.M., Murphy J.R., vanderSpek J.C. Interleukin 7 (IL-7) receptor-specific cell killing by DAB389 IL-7: a novel agent for the elimination of IL-7 receptor positive cells. Bioconjug. Chem. 1998, 9:201.
35. Tang S.T., Wang M., Lamberth K., Harndahl M., Dziegiel M.H., Claesson M.H., Buus S., Lund O. MHC-I-restricted epitopes conserved among variola and other related orthopoxviruses are recognized by T cells 30years after vaccination. Arch. Virol. 2008, 153:1833.
36. Taubenberger J.K., Morens D.M. The pathology of influenza virus infections. Annu. Rev. Pathol. 2008, 3:499.
37. Turner M.J., Jellison E.R., Lingenheld E.G., Puddington L., Lefrancois L. Avidity maturation of memory CD8 T cells is limited by self-antigen expression. J. Exp. Med. 2008, 205:1859.
38. Wherry E.J., McElhaugh M.J., Eisenlohr L.C. Generation of CD8(+) T cell memory in response to low, high, and excessive levels of epitope. J. Immunol. 2002, 168:4455.
39. Williams D.P., Snider C.E., Strom T.B., Murphy J.R. Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J. Biol. Chem. 1990, 265:11885.
40. Williams D.P., Wen Z., Watson R.S., Boyd J., Strom T.B., Murphy J.R. Cellular processing of the interleukin-2 fusion toxin DAB486-IL-2 and efficient delivery of diphtheria fragment A to the cytosol of target cells requires Arg194. J. Biol. Chem. 1990, 265:20673.